Contact | 
Print version | 
PDF version | 
Send article | 
RSS feed
Millipore and Novo Nordisk Expand Agreement to Supply Biopharmaceutical Market with Recombinant Human Insulin
Millipore gains long-term exclusive worldwide rights to distribute Novo Nordisk's insulin for cell culture applications
17 Aug 2007 -
Millipore Corporation announced an expansion of its agreement with Novo Nordisk to provide the biopharmaceutical market with recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs.
Under the terms of the agreement, Millipore will have exclusive worldwide rights to market and sell Novo Nordisk's recombinant human insulin, branded by Millipore as Incelligent(TM) SG and Incelligent(TM) AF, for cell culture media applications. The two insulin products are manufactured in separate and independent facilities thereby offering greater supply chain security to customers.
Cell culture supplements are products that help engineered cells to efficiently produce the proteins that are the basis of biologic drugs. Incelligent(TM) is available in a standard grade and in an animal-free version, which uses no animal-derived products in its manufacturing process. The use of animal-free supplements reduces risk and eases regulatory concerns for biopharmaceutical manufacturers.
The current long-term supply agreement between Millipore and Novo Nordisk was extended for several years and ensures that biopharmaceutical manufacturers will have a guaranteed, secure supply of insulin to use in the production of biologic drugs and the development of new cell lines. For the first time ever, customers have a dependable multi-year supply solution for animal-free insulin.
Top
